Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib Plus Vemurafenib in BRAF V600E-mutant Metastatic Colorectal Cancer
NCT06008119Phase 3Recruiting
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tunlametinib in colorectal cancer (CRC) (2 arms), sponsored by Shanghai KeChow Pharmaceuticals. Primary endpoint: Progression-Free Survival at 12 months. Started Oct 2023; status: recruiting.
02
Drugs
tunlametinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06008119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008119.